View in EDS HTML Full Text PDF Full Text

Highly effective combination of BRG1/BRM inhibitor with BET inhibitor or decitabine for high-risk MECOM-rearranged AML.

Saved in:
Bibliographic Details
Title: Highly effective combination of BRG1/BRM inhibitor with BET inhibitor or decitabine for high-risk MECOM-rearranged AML.
Authors: Fiskus W; The University of Texas M.D. Anderson Cancer Center Houston Texas United States., Mill CP; The University of Texas M.D. Anderson Cancer Center Houston Texas United States., Piel J; Foghorn Therapeutics Cambridge Massachusetts United States., Collins M; Foghorn Therapeutics Cambridge Massachusetts United States., Hentemann M; Foghorn Therapeutics Cambridge Massachusetts United States., Cuglievan B; The University of Texas M.D. Anderson Cancer Center Houston Texas United States., Birdwell CE; The University of Texas M.D. Anderson Cancer Center Houston Texas United States., Das K; The University of Texas M.D. Anderson Cancer Center Houston Texas United States., Davis JA; The University of Texas M.D. Anderson Cancer Center Houston Texas United States., Hou H; The University of Texas M.D. Anderson Cancer Center Houston Texas United States., Jain A; Baylor College of Medicine Houston Texas United States., Malovannaya A; Baylor College of Medicine Houston Texas United States., Flores LB; The University of Texas M.D. Anderson Cancer Center Houston Texas United States., Kadia TM; The University of Texas M.D. Anderson Cancer Center Houston Texas United States., Daver N; The University of Texas M.D. Anderson Cancer Center Houston Texas United States., Sasaki K; The University of Texas M.D. Anderson Cancer Center Houston Texas United States., Takahashi K; The University of Texas M.D. Anderson Cancer Center Houston Texas United States., Hammond D; The University of Texas M.D. Anderson Cancer Center Houston Texas United States., Wang J; The University of Texas M.D. Anderson Cancer Center Houston Texas United States., Loghavi S; The University of Texas M.D. Anderson Cancer Center Houston Texas United States., Su X; The University of Texas M.D. Anderson Cancer Center Houston Texas United States., DiNardo CD; The University of Texas M.D. Anderson Cancer Center Houston Texas United States., Delwel R; Erasmus MC Cancer Institute Rotterdam The Netherlands., Bhalla KN; The University of Texas M.D. Anderson Cancer Center Houston Texas United States.
Source: HemaSphere [Hemasphere] 2026 Jan 15; Vol. 10 (1), pp. e70289. Date of Electronic Publication: 2026 Jan 15 (Print Publication: 2026).
Publication Type: Journal Article
Journal Info: Publisher: Wiley Country of Publication: United States NLM ID: 101740619 Publication Model: eCollection Cited Medium: Internet ISSN: 2572-9241 (Electronic) Linking ISSN: 25729241 NLM ISO Abbreviation: Hemasphere Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41551728
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Highly effective combination of BRG1/BRM inhibitor with BET inhibitor or decitabine for high-risk MECOM-rearranged AML.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Fiskus+W%22">Fiskus W</searchLink>; The University of Texas M.D. Anderson Cancer Center Houston Texas United States.<br /><searchLink fieldCode="AU" term="%22Mill+CP%22">Mill CP</searchLink>; The University of Texas M.D. Anderson Cancer Center Houston Texas United States.<br /><searchLink fieldCode="AU" term="%22Piel+J%22">Piel J</searchLink>; Foghorn Therapeutics Cambridge Massachusetts United States.<br /><searchLink fieldCode="AU" term="%22Collins+M%22">Collins M</searchLink>; Foghorn Therapeutics Cambridge Massachusetts United States.<br /><searchLink fieldCode="AU" term="%22Hentemann+M%22">Hentemann M</searchLink>; Foghorn Therapeutics Cambridge Massachusetts United States.<br /><searchLink fieldCode="AU" term="%22Cuglievan+B%22">Cuglievan B</searchLink>; The University of Texas M.D. Anderson Cancer Center Houston Texas United States.<br /><searchLink fieldCode="AU" term="%22Birdwell+CE%22">Birdwell CE</searchLink>; The University of Texas M.D. Anderson Cancer Center Houston Texas United States.<br /><searchLink fieldCode="AU" term="%22Das+K%22">Das K</searchLink>; The University of Texas M.D. Anderson Cancer Center Houston Texas United States.<br /><searchLink fieldCode="AU" term="%22Davis+JA%22">Davis JA</searchLink>; The University of Texas M.D. Anderson Cancer Center Houston Texas United States.<br /><searchLink fieldCode="AU" term="%22Hou+H%22">Hou H</searchLink>; The University of Texas M.D. Anderson Cancer Center Houston Texas United States.<br /><searchLink fieldCode="AU" term="%22Jain+A%22">Jain A</searchLink>; Baylor College of Medicine Houston Texas United States.<br /><searchLink fieldCode="AU" term="%22Malovannaya+A%22">Malovannaya A</searchLink>; Baylor College of Medicine Houston Texas United States.<br /><searchLink fieldCode="AU" term="%22Flores+LB%22">Flores LB</searchLink>; The University of Texas M.D. Anderson Cancer Center Houston Texas United States.<br /><searchLink fieldCode="AU" term="%22Kadia+TM%22">Kadia TM</searchLink>; The University of Texas M.D. Anderson Cancer Center Houston Texas United States.<br /><searchLink fieldCode="AU" term="%22Daver+N%22">Daver N</searchLink>; The University of Texas M.D. Anderson Cancer Center Houston Texas United States.<br /><searchLink fieldCode="AU" term="%22Sasaki+K%22">Sasaki K</searchLink>; The University of Texas M.D. Anderson Cancer Center Houston Texas United States.<br /><searchLink fieldCode="AU" term="%22Takahashi+K%22">Takahashi K</searchLink>; The University of Texas M.D. Anderson Cancer Center Houston Texas United States.<br /><searchLink fieldCode="AU" term="%22Hammond+D%22">Hammond D</searchLink>; The University of Texas M.D. Anderson Cancer Center Houston Texas United States.<br /><searchLink fieldCode="AU" term="%22Wang+J%22">Wang J</searchLink>; The University of Texas M.D. Anderson Cancer Center Houston Texas United States.<br /><searchLink fieldCode="AU" term="%22Loghavi+S%22">Loghavi S</searchLink>; The University of Texas M.D. Anderson Cancer Center Houston Texas United States.<br /><searchLink fieldCode="AU" term="%22Su+X%22">Su X</searchLink>; The University of Texas M.D. Anderson Cancer Center Houston Texas United States.<br /><searchLink fieldCode="AU" term="%22DiNardo+CD%22">DiNardo CD</searchLink>; The University of Texas M.D. Anderson Cancer Center Houston Texas United States.<br /><searchLink fieldCode="AU" term="%22Delwel+R%22">Delwel R</searchLink>; Erasmus MC Cancer Institute Rotterdam The Netherlands.<br /><searchLink fieldCode="AU" term="%22Bhalla+KN%22">Bhalla KN</searchLink>; The University of Texas M.D. Anderson Cancer Center Houston Texas United States.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101740619%22">HemaSphere</searchLink> [Hemasphere] 2026 Jan 15; Vol. 10 (1), pp. e70289. <i>Date of Electronic Publication: </i>2026 Jan 15 (<i>Print Publication: </i>2026).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Wiley%22">Wiley </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101740619 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Internet <i>ISSN: </i>2572-9241 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2225729241%22">25729241 </searchLink><i>NLM ISO Abbreviation: </i>Hemasphere <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41551728
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1002/hem3.70289
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: e70289
    Titles:
      – TitleFull: Highly effective combination of BRG1/BRM inhibitor with BET inhibitor or decitabine for high-risk MECOM-rearranged AML.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Fiskus W
      – PersonEntity:
          Name:
            NameFull: Mill CP
      – PersonEntity:
          Name:
            NameFull: Piel J
      – PersonEntity:
          Name:
            NameFull: Collins M
      – PersonEntity:
          Name:
            NameFull: Hentemann M
      – PersonEntity:
          Name:
            NameFull: Cuglievan B
      – PersonEntity:
          Name:
            NameFull: Birdwell CE
      – PersonEntity:
          Name:
            NameFull: Das K
      – PersonEntity:
          Name:
            NameFull: Davis JA
      – PersonEntity:
          Name:
            NameFull: Hou H
      – PersonEntity:
          Name:
            NameFull: Jain A
      – PersonEntity:
          Name:
            NameFull: Malovannaya A
      – PersonEntity:
          Name:
            NameFull: Flores LB
      – PersonEntity:
          Name:
            NameFull: Kadia TM
      – PersonEntity:
          Name:
            NameFull: Daver N
      – PersonEntity:
          Name:
            NameFull: Sasaki K
      – PersonEntity:
          Name:
            NameFull: Takahashi K
      – PersonEntity:
          Name:
            NameFull: Hammond D
      – PersonEntity:
          Name:
            NameFull: Wang J
      – PersonEntity:
          Name:
            NameFull: Loghavi S
      – PersonEntity:
          Name:
            NameFull: Su X
      – PersonEntity:
          Name:
            NameFull: DiNardo CD
      – PersonEntity:
          Name:
            NameFull: Delwel R
      – PersonEntity:
          Name:
            NameFull: Bhalla KN
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 15
              M: 01
              Text: 2026 Jan 15
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 2572-9241
          Numbering:
            – Type: volume
              Value: 10
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: HemaSphere
              Type: main
ResultId 1